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sion (N = 556) or anxiety (N = 158) in addition to
migraine equated to signiﬁcantly greater outpatient, pre-
scription drug, and total medical costs compared to a
healthy comparator group. The differential in total costs
(medical plus productivity) between migraine sufferers
with comorbid anxiety ($4562, p < 0.0001) or comorbid
depression ($6193, p < 0.0001) and the healthy cohort
was substantially greater than the differential between
migraine sufferers without these comorbidities and their
healthy matches ($3638, p < 0.0001). CONCLUSIONS:
These results demonstrate and quantify the economic
burden in terms of direct and indirect costs to employers
of migraine alone and migraine in conjunction with
depression or anxiety.
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OBJECTIVE: To assess, via Monte Carlo simulation, the
per-attack drug acquisition cost and effectiveness (pro-
portion of patients pain-free two hours post-dose) of ﬁve
oral triptan strategies for treatment of acute migraine
headaches. METHODS: A Monte Carlo simulation
model was used to estimate the average number of
patients needed to treat (NNT), relative to placebo, to
achieve the efﬁcacy endpoint of one pain-free two hours
post-dose (pain-free patient). Efﬁcacy data was obtained
from a published meta-analysis of 53 triptan-speciﬁc 
clinical trials. A normal distribution for the proportion of
pain-free patients was used and was based on the means
and 95% conﬁdence intervals reported in the meta-
analysis. Single-dose acquisition costs, based on average
wholesale prices (2002US$), were applied to the NNT
results, allowing for a per-attack assessment of the cost
per pain-free patient. Oral triptans almotriptan, nara-
triptan, rizatriptan, sumatriptan and zolmitriptan were
assessed in the simulation. RESULTS: After 10,000 
iterations, the mean NNT (95% CI) to achieve one 
pain-free patient was 3.31 (2.97–3.71) for rizatriptan,
4.16 (2.83–6.54) for zolmitriptan, 5.06 (3.32–8.53) for
almotriptan, 5.14 (4.50–5.92) for sumatriptan and 7.26
(5.52–9.96) for naratriptan. The mean cost (95% CI) per
pain-free patient was $55.61 ($36.50–$93.70), $56.60
($50.81–$63.44), $75.34 ($51.34–$118.61), $88.27
($77.28–$101.70) and $145.27 ($110.38–$199.27) for
almotriptan, rizatriptan, zolmitriptan, sumatriptan and
naratriptan, respectively. Cost differences between
almotriptan and rizatriptan were relatively small, with 
38 percent of simulations resulting in cost savings per
pain-free patient favoring rizatriptan. CONCLUSIONS:
Inasmuch as the results suggested that almotriptan and
rizatriptan may be similar on a cost per pain-free patient
basis, the NNT results favored rizatriptan, with approx-
imately two fewer patients needed to treat to achieve one
pain-free patient. Future economic assessments, including
endpoints such as tablet consumption per attack and 
consistency across multiple attacks, may provide further
guidance as to the most cost-effective triptan strategies.
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OBJECTIVES: Use the outcomes effectiveness measure 
of a successfully treated patient to compare the cost-
effectiveness of Eletriptan to Sumatriptan. METHODS:
Data for the economic analysis was based on pooled data
from three randomized, double blind, placebo-controlled
phase III/B clinical trials. Logistic regression with SAS
GENMOD was used to ﬁt the model and the CON-
TRAST statement was used for the comparisons of inter-
est—the numbers of successfully treated patients. Three
measure of success were analyzed: patients with headache
response within 2 hours of triptan therapy, sustained to
24 hours; patients with headache response within 1 hour
of triptan therapy, sustained to 24 hours, and patients
who were pain free within 2 hours of triptan therapy, sus-
tained to 24 hours. The cost-effectiveness measure—cost
per successfully treated patient—was calculated as a ratio
of the total cost of treating all patients to the number 
of successfully treated patients for the comparison of
Eletriptan 40mg vs. Sumatriptan 100mg. The 95% con-
ﬁdence interval for the comparison group for each
outcome effectiveness measure was calculated by boot-
strapping techniques. RESULTS: The number of success-
fully treated patients for each of the 3 outcome measures
of effectiveness was statistically signiﬁcantly greater in the
Eletriptan 40mg groups compared to the Sumatriptan
100mg groups (P-values all =<.002). The 95% conﬁdence
interval ranges for each of the Eletriptan cost-
effectiveness results are smaller and the one for the 2-hour
pain free sustained measure does not overlap that of
Sumatriptan. CONCLUSIONS: The cost per successfully
treated patient is a new composite outcome measure 
of cost-effectiveness that was consistently lower for all
patients treated with Eletriptan 40mg compared to 
Sumatriptan 100mg. Cost-effectiveness using this
outcome measure empirically demonstrates the value for
the resources spent on migraine therapy.
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